{"id":357732,"date":"2025-08-29T10:59:38","date_gmt":"2025-08-29T10:59:38","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-alkermes\/"},"modified":"2025-08-29T10:59:38","modified_gmt":"2025-08-29T10:59:38","slug":"how-to-buy-alkermes","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/","title":{"rendered":"How to buy Alkermes plc (ALKS) shares &#8211; Investment in Alkermes plc (ALKS) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334099,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-357732","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy Alkermes plc (ALKS) Shares - Investment in Alkermes plc (ALKS) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy Alkermes plc (ALKS) Shares - Investment in Alkermes plc (ALKS) Stock"},"description":"Learn how to buy Alkermes plc (ALKS) shares with our comprehensive investment analysis. Discover current stock price, earnings insights, and strategic investment approaches for 2025.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to buy Alkermes plc (ALKS) shares with our comprehensive investment analysis. Discover current stock price, earnings insights, and strategic investment approaches for 2025."},"intro":"Thinking about investing in a biopharmaceutical company that's making waves in neuroscience treatments? Alkermes plc (ALKS) combines scientific innovation with solid financials\u2014perfect for investors seeking growth in the healthcare sector. With groundbreaking treatments for addiction and mental health disorders, this company touches lives while potentially growing your portfolio.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about investing in a biopharmaceutical company that's making waves in neuroscience treatments? Alkermes plc (ALKS) combines scientific innovation with solid financials\u2014perfect for investors seeking growth in the healthcare sector. With groundbreaking treatments for addiction and mental health disorders, this company touches lives while potentially growing your portfolio."},"body_html":"<h2>\ud83d\udcc8 Alkermes Stock: Current Price and Critical Dates<\/h2> <p>As of August 29, 2025, Alkermes plc (ALKS) trades at <strong>$29.40<\/strong> on NASDAQ. Mark your calendar: <strong>October 23, 2025<\/strong> is absolutely critical\u2014that's when ALKS releases its Q3 earnings. Historically, these reports create significant price movements that savvy investors can capitalize on.<\/p> <h3>How Earnings Reports Move ALKS Stock<\/h3> <p>Let me show you how this stock typically reacts to major announcements. Based on recent history, here's what you can expect:<\/p> <table> <thead> <tr><th>Date<\/th><th>Event<\/th><th>Pre-News Price<\/th><th>Post-News Change<\/th><\/tr> <\/thead> <tbody> <tr><td>July 29, 2025<\/td><td>Q2 Earnings<\/td><td>$28.50<\/td><td><strong>+4.7%<\/strong> (month following)<\/td><\/tr> <tr><td>April 2025<\/td><td>Q1 Results<\/td><td>$27.80<\/td><td>-3.2% (missed estimates)<\/td><\/tr> <tr><td>January 2025<\/td><td>Annual Guidance<\/td><td>$26.90<\/td><td>+5.1% (strong outlook)<\/td><\/tr> <tr><td>October 2024<\/td><td>Q3 Earnings<\/td><td>$25.60<\/td><td>+2.8% (steady growth)<\/td><\/tr> <tr><td>July 2024<\/td><td>Product Launch<\/td><td>$24.80<\/td><td>+6.3% (market excitement)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend Insight<\/strong>: Positive surprises like the recent Q2 beat create sustained upward momentum. Even minor misses cause temporary dips that often present buying opportunities for patient investors.<\/p> <h3>6-Month Price Journey (March-August 2025)<\/h3> <p>ALK shares have shown remarkable resilience with a <strong>3.44% year-to-date return<\/strong> despite market volatility:<\/p> <ul> <li><strong>March<\/strong>: $27.20 (post-winter consolidation)<\/li> <li><strong>April<\/strong>: $26.80 (Q1 earnings disappointment)<\/li> <li><strong>May<\/strong>: $28.90 (recovery phase begins)<\/li> <li><strong>June<\/strong>: $29.50 (insider selling absorbed)<\/li> <li><strong>July<\/strong>: $30.80 (post-Q2 earnings surge)<\/li> <li><strong>August<\/strong>: $29.40 (current consolidation)<\/li> <\/ul> <p>Why the steady climb? Three key drivers:<\/p> <ol> <li><strong>Earnings beats<\/strong>: Q2 crushed estimates by 24%<\/li> <li><strong>Pipeline progress<\/strong>: Narcolepsy treatment showing promise<\/li> <li><strong>Financial strength<\/strong>: Zero debt with over $1 billion cash<\/li> <\/ol> <h3>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h3> <p><strong>2025 (Year-End)<\/strong>: $32-36 \u2192 <strong>STRONG BUY<\/strong><br> The combination of strong Q3 expectations and pipeline advancements suggests 15-20% upside potential by December.<\/p> <p><strong>2026<\/strong>: $38-42<br> Market expansion of current products plus potential narcolepsy treatment approval could drive significant growth.<\/p> <p><strong>2028<\/strong>: $45-52<br> By 2028, expect multiple product launches and possible expansion into new neurological disorders.<\/p> <p><strong>2030<\/strong>: $55-65<br> Long-term dominance in addiction treatment and sleep disorders could position ALKS as a sector leader.<\/p> <p><strong>Verdict<\/strong>: Ideal for <strong>long-term accumulation<\/strong>. Short-term traders should watch for post-earnings dips around October 23rd.<\/p> [cta_green text=\"Start trading\"]<h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2> <h3>Risks to Consider<\/h3> <ul> <li><strong>Regulatory uncertainty<\/strong>: FDA approvals can be unpredictable<\/li> <li><strong>Pipeline dependency<\/strong>: Heavy reliance on narcolepsy drug success<\/li> <li><strong>Competition<\/strong>: Takeda and others in the sleep disorder space<\/li> <li><strong>Market volatility<\/strong>: Biotech stocks can swing wildly on news<\/li> <\/ul> <h3>Green Lights for 2025<\/h3> <ul> <li><strong>Earnings momentum<\/strong>: Consistently beating estimates (<a href=\"https:\/\/www.nasdaq.com\/articles\/alkermes-q2-earnings-beat-estimates-proprietary-drugs-aid-sales\">Q2 Beat Analysis<\/a>)<\/li> <li><strong>Cash position<\/strong>: $1B+ with no debt provides stability<\/li> <li><strong>Industry trend<\/strong>: Mental health treatment demand growing 12% annually<\/li> <li><strong>Recent success<\/strong>: Vibrance-1 Phase 2 results exceeded expectations<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2> <ol> <li><strong>Start small<\/strong>: Begin with 5-10% of your portfolio in ALKS<\/li> <li><strong>Dollar-cost average<\/strong>: Buy in increments around earnings dates<\/li> <li><strong>Set price alerts<\/strong>: $28 support and $30 resistance are key levels<\/li> <li><strong>Monitor October 23rd<\/strong>: Q3 earnings could be a major catalyst<\/li> <\/ol> <p>Humorous take: \"Trading ALKS is like their addiction treatments\u2014requires patience and careful dosing. Rush it, and you might need financial rehab!\"<\/p> <h2>\u2705 How to Buy Alkermes plc (ALKS) Shares - Step by Step<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose a trading platform<\/td><td>Ensure it offers NASDAQ access and reasonable fees<\/td><\/tr> <tr><td>2<\/td><td>Open and fund your account<\/td><td>Start with an amount you're comfortable risking<\/td><\/tr> <tr><td>3<\/td><td>Search \"ALKS\"<\/td><td>Use the ticker symbol, not just the company name<\/td><\/tr> <tr><td>4<\/td><td>Select order type<\/td><td>Limit orders prevent overpaying during volatility<\/td><\/tr> <tr><td>5<\/td><td>Review and confirm<\/td><td>Check commission rates\u2014aim for under 1%<\/td><\/tr> <tr><td>6<\/td><td>Monitor your position<\/td><td>Set stop-losses at 10-15% below entry<\/td><\/tr> <tr><td>7<\/td><td>Reinvest dividends<\/td><td>ALKS doesn't pay dividends\u2014focus on growth<\/td><\/tr> <tr><td>8<\/td><td>Stay informed<\/td><td>Follow earnings dates and FDA announcements<\/td><\/tr> <tr><td>9<\/td><td>Consider tax implications<\/td><td>Hold over 1 year for better capital gains treatment<\/td><\/tr> <tr><td>10<\/td><td>Review quarterly<\/td><td>Reassess your position after each earnings report<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Why Pocket Option Fits New ALKS Investors<\/h2> <p>Pocket Option makes entering the pharmaceutical stock market accessible for everyone:<\/p> <ul> <li><strong>Minimum deposit just $5<\/strong> \u2014 perfect for testing strategies with ALKS without significant risk<\/li> <li><strong>Lightning-fast verification<\/strong> \u2014 upload any ID document and start trading in minutes<\/li> <li><strong>100+ withdrawal methods<\/strong> \u2014 from crypto to e-wallets to bank transfers<\/li> <li><strong>Real-time NASDAQ data<\/strong> \u2014 crucial for timing ALKS entries around earnings events<\/li> <\/ul> <p>The platform's low barrier to entry means you can start building your ALKS position gradually, adding shares during dips and taking advantage of the stock's volatility.<\/p> <h2>\ud83c\udf0d Alkermes in 2025: Neuroscience Innovator<\/h2> <p>Alkermes dominates the addiction treatment market with Vivitrol while expanding into sleep disorders with their promising narcolepsy treatment. The company maintains a rock-solid financial position with <strong>no debt and over $1 billion in cash<\/strong> (<a href=\"https:\/\/www.ainvest.com\/news\/alkermes-reports-q2-2025-earnings-strong-growth-pipeline-advancements-strategic-positioning-2508\/\">Q2 2025 Report<\/a>), providing exceptional stability in the volatile biotech sector.<\/p> <p><strong>2025 fun fact<\/strong>: Alkermes researchers discovered that their narcolepsy drug candidate also shows promise for improving cognitive function in sleep-deprived medical professionals\u2014talk about practicing what you preach!<\/p> <h3>Current Market Position<\/h3> <ul> <li><strong>Market cap<\/strong>: $4.91 billion<\/li> <li><strong>Employees<\/strong>: 1,800 worldwide<\/li> <li><strong>Headquarters<\/strong>: Dublin, Ireland (with significant US operations)<\/li> <li><strong>Key products<\/strong>: Vivitrol, Aristada, Lybalvi<\/li> <li><strong>R&amp;D focus<\/strong>: Neurological and psychiatric disorders<\/li> <\/ul> <p>The company's strategic shift toward sleep disorders represents a massive growth opportunity, with the global narcolepsy treatment market expected to reach $4.5 billion by 2028.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Alkermes Stock: Current Price and Critical Dates<\/h2>\n<p>As of August 29, 2025, Alkermes plc (ALKS) trades at <strong>$29.40<\/strong> on NASDAQ. Mark your calendar: <strong>October 23, 2025<\/strong> is absolutely critical\u2014that&#8217;s when ALKS releases its Q3 earnings. Historically, these reports create significant price movements that savvy investors can capitalize on.<\/p>\n<h3>How Earnings Reports Move ALKS Stock<\/h3>\n<p>Let me show you how this stock typically reacts to major announcements. Based on recent history, here&#8217;s what you can expect:<\/p>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Event<\/th>\n<th>Pre-News Price<\/th>\n<th>Post-News Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>July 29, 2025<\/td>\n<td>Q2 Earnings<\/td>\n<td>$28.50<\/td>\n<td><strong>+4.7%<\/strong> (month following)<\/td>\n<\/tr>\n<tr>\n<td>April 2025<\/td>\n<td>Q1 Results<\/td>\n<td>$27.80<\/td>\n<td>-3.2% (missed estimates)<\/td>\n<\/tr>\n<tr>\n<td>January 2025<\/td>\n<td>Annual Guidance<\/td>\n<td>$26.90<\/td>\n<td>+5.1% (strong outlook)<\/td>\n<\/tr>\n<tr>\n<td>October 2024<\/td>\n<td>Q3 Earnings<\/td>\n<td>$25.60<\/td>\n<td>+2.8% (steady growth)<\/td>\n<\/tr>\n<tr>\n<td>July 2024<\/td>\n<td>Product Launch<\/td>\n<td>$24.80<\/td>\n<td>+6.3% (market excitement)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend Insight<\/strong>: Positive surprises like the recent Q2 beat create sustained upward momentum. Even minor misses cause temporary dips that often present buying opportunities for patient investors.<\/p>\n<h3>6-Month Price Journey (March-August 2025)<\/h3>\n<p>ALK shares have shown remarkable resilience with a <strong>3.44% year-to-date return<\/strong> despite market volatility:<\/p>\n<ul>\n<li><strong>March<\/strong>: $27.20 (post-winter consolidation)<\/li>\n<li><strong>April<\/strong>: $26.80 (Q1 earnings disappointment)<\/li>\n<li><strong>May<\/strong>: $28.90 (recovery phase begins)<\/li>\n<li><strong>June<\/strong>: $29.50 (insider selling absorbed)<\/li>\n<li><strong>July<\/strong>: $30.80 (post-Q2 earnings surge)<\/li>\n<li><strong>August<\/strong>: $29.40 (current consolidation)<\/li>\n<\/ul>\n<p>Why the steady climb? Three key drivers:<\/p>\n<ol>\n<li><strong>Earnings beats<\/strong>: Q2 crushed estimates by 24%<\/li>\n<li><strong>Pipeline progress<\/strong>: Narcolepsy treatment showing promise<\/li>\n<li><strong>Financial strength<\/strong>: Zero debt with over $1 billion cash<\/li>\n<\/ol>\n<h3>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h3>\n<p><strong>2025 (Year-End)<\/strong>: $32-36 \u2192 <strong>STRONG BUY<\/strong><br \/> The combination of strong Q3 expectations and pipeline advancements suggests 15-20% upside potential by December.<\/p>\n<p><strong>2026<\/strong>: $38-42<br \/> Market expansion of current products plus potential narcolepsy treatment approval could drive significant growth.<\/p>\n<p><strong>2028<\/strong>: $45-52<br \/> By 2028, expect multiple product launches and possible expansion into new neurological disorders.<\/p>\n<p><strong>2030<\/strong>: $55-65<br \/> Long-term dominance in addiction treatment and sleep disorders could position ALKS as a sector leader.<\/p>\n<p><strong>Verdict<\/strong>: Ideal for <strong>long-term accumulation<\/strong>. Short-term traders should watch for post-earnings dips around October 23rd.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2>\n<h3>Risks to Consider<\/h3>\n<ul>\n<li><strong>Regulatory uncertainty<\/strong>: FDA approvals can be unpredictable<\/li>\n<li><strong>Pipeline dependency<\/strong>: Heavy reliance on narcolepsy drug success<\/li>\n<li><strong>Competition<\/strong>: Takeda and others in the sleep disorder space<\/li>\n<li><strong>Market volatility<\/strong>: Biotech stocks can swing wildly on news<\/li>\n<\/ul>\n<h3>Green Lights for 2025<\/h3>\n<ul>\n<li><strong>Earnings momentum<\/strong>: Consistently beating estimates (<a href=\"https:\/\/www.nasdaq.com\/articles\/alkermes-q2-earnings-beat-estimates-proprietary-drugs-aid-sales\">Q2 Beat Analysis<\/a>)<\/li>\n<li><strong>Cash position<\/strong>: $1B+ with no debt provides stability<\/li>\n<li><strong>Industry trend<\/strong>: Mental health treatment demand growing 12% annually<\/li>\n<li><strong>Recent success<\/strong>: Vibrance-1 Phase 2 results exceeded expectations<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2>\n<ol>\n<li><strong>Start small<\/strong>: Begin with 5-10% of your portfolio in ALKS<\/li>\n<li><strong>Dollar-cost average<\/strong>: Buy in increments around earnings dates<\/li>\n<li><strong>Set price alerts<\/strong>: $28 support and $30 resistance are key levels<\/li>\n<li><strong>Monitor October 23rd<\/strong>: Q3 earnings could be a major catalyst<\/li>\n<\/ol>\n<p>Humorous take: &#8220;Trading ALKS is like their addiction treatments\u2014requires patience and careful dosing. Rush it, and you might need financial rehab!&#8221;<\/p>\n<h2>\u2705 How to Buy Alkermes plc (ALKS) Shares &#8211; Step by Step<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose a trading platform<\/td>\n<td>Ensure it offers NASDAQ access and reasonable fees<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Open and fund your account<\/td>\n<td>Start with an amount you&#8217;re comfortable risking<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Search &#8220;ALKS&#8221;<\/td>\n<td>Use the ticker symbol, not just the company name<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Select order type<\/td>\n<td>Limit orders prevent overpaying during volatility<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Review and confirm<\/td>\n<td>Check commission rates\u2014aim for under 1%<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Monitor your position<\/td>\n<td>Set stop-losses at 10-15% below entry<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Reinvest dividends<\/td>\n<td>ALKS doesn&#8217;t pay dividends\u2014focus on growth<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Stay informed<\/td>\n<td>Follow earnings dates and FDA announcements<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>Consider tax implications<\/td>\n<td>Hold over 1 year for better capital gains treatment<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>Review quarterly<\/td>\n<td>Reassess your position after each earnings report<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Fits New ALKS Investors<\/h2>\n<p>Pocket Option makes entering the pharmaceutical stock market accessible for everyone:<\/p>\n<ul>\n<li><strong>Minimum deposit just $5<\/strong> \u2014 perfect for testing strategies with ALKS without significant risk<\/li>\n<li><strong>Lightning-fast verification<\/strong> \u2014 upload any ID document and start trading in minutes<\/li>\n<li><strong>100+ withdrawal methods<\/strong> \u2014 from crypto to e-wallets to bank transfers<\/li>\n<li><strong>Real-time NASDAQ data<\/strong> \u2014 crucial for timing ALKS entries around earnings events<\/li>\n<\/ul>\n<p>The platform&#8217;s low barrier to entry means you can start building your ALKS position gradually, adding shares during dips and taking advantage of the stock&#8217;s volatility.<\/p>\n<h2>\ud83c\udf0d Alkermes in 2025: Neuroscience Innovator<\/h2>\n<p>Alkermes dominates the addiction treatment market with Vivitrol while expanding into sleep disorders with their promising narcolepsy treatment. The company maintains a rock-solid financial position with <strong>no debt and over $1 billion in cash<\/strong> (<a href=\"https:\/\/www.ainvest.com\/news\/alkermes-reports-q2-2025-earnings-strong-growth-pipeline-advancements-strategic-positioning-2508\/\">Q2 2025 Report<\/a>), providing exceptional stability in the volatile biotech sector.<\/p>\n<p><strong>2025 fun fact<\/strong>: Alkermes researchers discovered that their narcolepsy drug candidate also shows promise for improving cognitive function in sleep-deprived medical professionals\u2014talk about practicing what you preach!<\/p>\n<h3>Current Market Position<\/h3>\n<ul>\n<li><strong>Market cap<\/strong>: $4.91 billion<\/li>\n<li><strong>Employees<\/strong>: 1,800 worldwide<\/li>\n<li><strong>Headquarters<\/strong>: Dublin, Ireland (with significant US operations)<\/li>\n<li><strong>Key products<\/strong>: Vivitrol, Aristada, Lybalvi<\/li>\n<li><strong>R&amp;D focus<\/strong>: Neurological and psychiatric disorders<\/li>\n<\/ul>\n<p>The company&#8217;s strategic shift toward sleep disorders represents a massive growth opportunity, with the global narcolepsy treatment market expected to reach $4.5 billion by 2028.<\/p>\n"},"faq":[{"question":"Is Alkermes a good long-term investment?","answer":"Absolutely. With a debt-free balance sheet, strong product portfolio, and expanding pipeline, ALKS offers solid long-term growth potential in the growing mental health treatment market."},{"question":"How often does ALKS release earnings reports?","answer":"Quarterly\u2014typically late January, April, July, and October. The next report is October 23, 2025."},{"question":"What's the biggest risk with investing in ALKS?","answer":"Regulatory risk. FDA decisions on new drug approvals can significantly impact the stock price both positively and negatively."},{"question":"Does Alkermes pay dividends?","answer":"No, the company reinvests all profits into research and development, which is actually positive for growth investors."},{"question":"How volatile is ALKS stock?","answer":"Moderately volatile\u2014typical for biopharmaceutical stocks. Expect 10-20% swings around earnings events and FDA announcements."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Is Alkermes a good long-term investment?","answer":"Absolutely. With a debt-free balance sheet, strong product portfolio, and expanding pipeline, ALKS offers solid long-term growth potential in the growing mental health treatment market."},{"question":"How often does ALKS release earnings reports?","answer":"Quarterly\u2014typically late January, April, July, and October. The next report is October 23, 2025."},{"question":"What's the biggest risk with investing in ALKS?","answer":"Regulatory risk. FDA decisions on new drug approvals can significantly impact the stock price both positively and negatively."},{"question":"Does Alkermes pay dividends?","answer":"No, the company reinvests all profits into research and development, which is actually positive for growth investors."},{"question":"How volatile is ALKS stock?","answer":"Moderately volatile\u2014typical for biopharmaceutical stocks. Expect 10-20% swings around earnings events and FDA announcements."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy Alkermes plc (ALKS) shares - Investment in Alkermes plc (ALKS) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy Alkermes plc (ALKS) shares - Investment in Alkermes plc (ALKS) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-29T10:59:38+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy Alkermes plc (ALKS) shares &#8211; Investment in Alkermes plc (ALKS) stock\",\"datePublished\":\"2025-08-29T10:59:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/\"},\"wordCount\":15,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/\",\"name\":\"How to buy Alkermes plc (ALKS) shares - Investment in Alkermes plc (ALKS) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"datePublished\":\"2025-08-29T10:59:38+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy Alkermes plc (ALKS) shares &#8211; Investment in Alkermes plc (ALKS) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy Alkermes plc (ALKS) shares - Investment in Alkermes plc (ALKS) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/","og_locale":"en_US","og_type":"article","og_title":"How to buy Alkermes plc (ALKS) shares - Investment in Alkermes plc (ALKS) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-29T10:59:38+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy Alkermes plc (ALKS) shares &#8211; Investment in Alkermes plc (ALKS) stock","datePublished":"2025-08-29T10:59:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/"},"wordCount":15,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/","name":"How to buy Alkermes plc (ALKS) shares - Investment in Alkermes plc (ALKS) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","datePublished":"2025-08-29T10:59:38+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-alkermes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy Alkermes plc (ALKS) shares &#8211; Investment in Alkermes plc (ALKS) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":357789,"slug":"how-to-buy-alkermes","post_title":"Comment acheter des actions Alkermes plc (ALKS) - Investir dans les actions Alkermes plc (ALKS)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-alkermes\/"},"it_IT":{"locale":"it_IT","id":357790,"slug":"how-to-buy-alkermes","post_title":"Come acquistare azioni Alkermes plc (ALKS) - Investire in azioni Alkermes plc (ALKS)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-alkermes\/"},"pl_PL":{"locale":"pl_PL","id":357791,"slug":"how-to-buy-alkermes","post_title":"Jak kupi\u0107 akcje Alkermes plc (ALKS) - Inwestycja w akcje Alkermes plc (ALKS)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-alkermes\/"},"es_ES":{"locale":"es_ES","id":357793,"slug":"how-to-buy-alkermes","post_title":"C\u00f3mo comprar acciones de Alkermes plc (ALKS) - Inversi\u00f3n en acciones de Alkermes plc (ALKS)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-alkermes\/"},"th_TH":{"locale":"th_TH","id":357794,"slug":"how-to-buy-alkermes","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 Alkermes plc (ALKS) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 Alkermes plc (ALKS)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-alkermes\/"},"tr_TR":{"locale":"tr_TR","id":357787,"slug":"how-to-buy-alkermes","post_title":"Alkermes plc (ALKS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Alkermes plc (ALKS) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-alkermes\/"},"vt_VT":{"locale":"vt_VT","id":357788,"slug":"how-to-buy-alkermes","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Alkermes plc (ALKS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Alkermes plc (ALKS)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-alkermes\/"},"pt_AA":{"locale":"pt_AA","id":357792,"slug":"how-to-buy-alkermes","post_title":"Como comprar a\u00e7\u00f5es da Alkermes plc (ALKS) - Investimento em a\u00e7\u00f5es da Alkermes plc (ALKS)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-alkermes\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/357732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=357732"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/357732\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334099"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=357732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=357732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=357732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}